GAS5 and ovarian carcinoma: Growth arrest-specific 5 is downregulated in ovarian cancer, with this low expression associated with shorter disease-free period and lower overall survival rate of ovarian cancer patients (Gao et al., 2015; Li et al., 2016; Zhao et al., 2018; Long et al., 2019).